Multiple Anti-Cancer Agents for Prostate Cancer
(PROSPECTOR Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Are You a Good Fit for This Trial?
This trial is for adults with prostate cancer that has spread to other parts of the body (metastatic). Participants should be in generally stable health and able to undergo study procedures. People with certain serious medical conditions or who can't safely receive the study drugs may not be eligible.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation (Part A)
A dose escalation phase to identify dose limiting toxicities, characterize safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy.
Dose Optimization/Expansion (Part B)
A dose optimization/expansion phase to inform recommended Phase 3 dose and explore efficacy with PSA50 rate as primary endpoints.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AZD2265 (FPI-2265)
- AZD2287
- AZD9574
- Docetaxel
Trial Overview
The study is testing several anti-cancer treatments, including chemotherapy (Docetaxel), new experimental drugs (AZD9574, AZD2265), and an imaging agent (AZD2287) in people with metastatic prostate cancer. The main goals are to check safety and early effectiveness.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Active Control
Participants will receive AZD9574 chosen from the DE phase once daily in combination with AZD2265 (FPI-2265) Q6W.
Participants will receive escalating dose levels of AZD9574 once daily in combination with AZD2265 (FPI-2265) once every 6 weeks (Q6W).
Participants will receive AZD2265 (FPI-2265) monotherapy Q6W.
Participants will receive docetaxel as a standard of care (SoC) once every 3 weeks (Q3W).
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.